VSTM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

VS

Mkt Cap

$784.7M

Volume

5.37M

Next Earnings

November 3rd

Loading chart

VS

VSTMVerastem, Inc.

VSTM

Pay with—

Available Balance0.00

VS

Mkt Cap

$835.9M

Volume

5.37M

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?Verastem (VSTM) closed at $8.38 with a mean analyst price target of $15, suggesting 79% upside potential. The stock has gained 14.5% over the past four weeks. Analysts have revised earnings estimates higher, and VSTM holds a Zacks Rank #2 (Buy) rating. However, the article cautions that price targets should not be the sole basis for investment decisions, as they are often overly optimistic.Zacks Investment Research · Oct 12, 2026

Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?Genmab shares rallied 10.7% following positive phase III trial data for epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma. The stock's consensus EPS estimate was revised 8.7% higher over the past 30 days, though earnings are expected to decline 43.1% year-over-year while revenues grow 15.7%. The stock carries a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Oct 6, 2026

Verastem Stock Skyrockets 121% in 3 Months: Here Is WhyVerastem (VSTM) shares have surged 121% over three months, driven by accelerating sales of ovarian cancer drug Avmapki Fakzynja Co-Pack, which generated $25.1 million in Q2 2026 revenues (up 1,095% YoY), and growing optimism around VS-7375, a KRAS G12D inhibitor in phase II trials across pancreatic, lung, and colorectal cancers. The company expects VS-7375 data in October 2026 and plans FDA meetings before year-end to discuss phase III pivotal trial designs.Zacks Investment Research · Sep 8, 2026

KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsightThe KRAS inhibitors market is projected to grow at a 35% CAGR from 2025-2034, driven by rising cancer incidence and a robust pipeline of targeted therapies for KRAS mutations across multiple cancer types.GlobeNewswire Inc. · Nov 12, 2025

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy HeadwindsDespite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.Benzinga · Jul 23, 2025

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the ChargeThe global cancer market is projected to surpass $900 billion by 2034, driven by advancements in cancer treatments from biotech companies like Oncolytics Biotech, Exelixis, Cardiff Oncology, ALX Oncology, and Verastem.Benzinga · Mar 8, 2025

Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - BenzingaEnphase Energy reported mixed Q2 results, leading to a rise in its stock price. Several other companies saw significant pre-market movements, both positive and negative, due to various news and earnings reports.Benzinga · Jul 24, 2024

Verastem, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswireThe Portnoy Law Firm has initiated an investigation into Verastem, Inc. (NASDAQ: VSTM) for potential securities fraud after the company disclosed serious adverse events in a clinical trial, causing a significant drop in its stock price.GlobeNewswire Inc. · Jul 10, 2024

Verastem: A Shocking Drop On 'Positive' Data (Maintain Buy)Verastem Oncology is on track to secure a drug approval for avutometinib, but their low cash position poses a significant risk. Find out why VSTM stock is a Buy.Seeking Alpha · May 26, 2024

Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study DataVerastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.Zacks Investment Research · May 24, 2024

to start trading

VS

VSTMVerastem, Inc.

VSTM

Pay with—

Available Balance0.00

Your PositionYou don't own any VSTM yet.

Related Tickers

Earnings